Griffipavixanthone induces apoptosis of human breast cancer MCF-7 cells in vitro.

Abstract

Griffipavixanthone (GPX) is a compound extracted from Garcinia oblongifolia Champ. But, no research has yet been done about the effect of GPX on breast cancer. We evaluated the proliferation of human breast cancer cells by CCK-8 assay and apoptosis by Annexin V (AV)-FITC and PI double staining. We used transwell assay to indicate the invasion and migration of MCF-7. To explore the molecular mechanism of GPX, we detected the mRNA and protein expression using qRT-PCR and Western blot. In this study, we evaluated if GPX could inhibit the proliferation of human breast cancer cell MCF-7 and T-47D with IC50 value of 9.64 ± 0.12µM and 10.2 1 ± 0.38µM at 48h. And the IC50 value of MCF-10A is 32.11 ± 0.21µM, which showed GPX had a tiny side effect for normal breast cells. Annexin V (AV)-FITC and PI double staining demonstrated firmly the apoptosis of MCF-7 resulting from GPX. Transwell assay indicated that GPX inhibited the invasion and migration of MCF-7. In addition, we found GPX cleaved caspase-8/9 and PARP, which play important roles in apoptotic pathway. Furthermore, through the Western blot assay, GPX increased the level of pro-apoptosis protein Bax and cytochrome C. On the contrary, GPX decreased the level of anti-apoptosis protein Bcl-2. Moreover, GPX increased the mRNA and protein expression level of p53 and its target genes, which indicated that GPX induced MCF-7 cell apoptosis by up-regulating p53 and Bax expression while suppressing Bcl-2 expression. All the results showed that GPX induces MCF-7 cell apoptosis and could be considered as a potential drug for breast cancer.